c-Myc-targeted therapy in breast cancer: A review of fundamentals and pharmacological Insights
Abstract
No abstract availableKeywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (151344/2022-1, 310290/2021-0)
This publication has 70 references indexed in Scilit:
- Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cellsInvestigational New Drugs, 2023
- Breast cancer in the era of precision medicineMolecular Biology Reports, 2022
- An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment PersistenceCancer Cell, 2021
- G‐Quadruplex‐Binding Small Molecule Induces Synthetic Lethality in Breast Cancer Cells by Inhibiting c‐MYC and BCL2 ExpressionChemBioChem, 2019
- Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancerInternational Journal of Cancer, 2019
- microRNA as a systemic intervention in the specific breast cancer subtypes with C‐MYC impacts; introducing subtype‐based appraisal toolJournal of Cellular Physiology, 2018
- Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applicationsTumor Biology, 2016
- Constitutive activation of STAT3 in breast cancer cells: A reviewInternational Journal of Cancer, 2015
- MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiencyTumor Biology, 2013
- Molecular modeling and biophysical analysis of the c-MYC NHE-III1 silencer elementJournal of Molecular Modeling, 2007